Pralatrexate
In the US, Pralatrexate (pralatrexate systemic) is a member of the drug class antimetabolites and is used to treat Lymphoma, Non-Hodgkin's Lymphoma and Peripheral T-cell Lymphoma.
US matches:
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
L01BA05
CAS registry number (Chemical Abstracts Service)
0146464-95-1
Chemical Formula
C23-H23-N7-O5
Molecular Weight
477
Therapeutic Category
Antineoplastic agent
Chemical Names
N-(4-{1-[(2,4-diaminopteridin-6-yl)methyl]but-3-yn-1-yl}benzoyl)-L-glutamic acid (IUPAC)
N-{4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}-L-glutamic acid (WHO)
(2S)-2-[[4-[(1RS)-1-[(2,4-Diaminopteridin-6-yl)methyl]but-3-ynyl]benzoyl]amino]pentanedioic acid (USAN)
10-Propargyl-10-deazaaminopterin
L-Glutamic acid, N-[4-[1-[(2,4-diamino-6-pteridinyl)methyl]-3-butynyl]benzoyl]- (USAN)
Foreign Names
- Pralatrexatum (Latin)
- Pralatrexat (German)
- Pralatrexate (French)
- Pralatrexato (Spanish)
Generic Names
- Pralatrexate (OS: USAN)
- PDX (IS)
- UNIIA8Q8I19Q20 (IS)
Brand Name
- Folotyn
Allos, United States
International Drug Name Search
Glossary
| Term | Definition |
|---|---|
| IUPAC | International Union of Pure and Applied Chemistry |
| IS | Inofficial Synonym |
| OS | Official Synonym |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
| USAN | United States Adopted Name |
| WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
